ESMO 2023 | Phase III clinical trials exploring targeted combination therapies for patients with UC

Petros Grivas, MD, PhD, University of Washington School of Medicine, Seattle, WA discusses two exciting Phase III trials which are currently testing targeted combination therapies versus standard of care chemotherapy in patients with urothelial carcinoma. The Phase III EV-302 (NCT04223856) trial demonstrated a significantly improved overall-survival (OS) and progression-free survival (PFS) enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated advanced urothelial carcinoma. The Phase III CheckMate-901 (NCT03036098) trial demonstrated a survival benefit with nivolumab plus chemotherapy versus chemotherapy alone in the first-line treatment of patients with unresectable or metastatic urothelial carcinoma. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.